Updated:
Novartis International AG
Vasant Narasimhan runs Novartis, the pure-play Swiss pharmaceutical firm formed in 1996 that spun off Alcon and Sandoz to focus on innovative medicines.
Novartis International AG
Novartis was formed in 1996 through the merger of Basel's two largest chemical and pharmaceutical firms, Ciba-Geigy and Sandoz. Under former CEO Daniel Vasella, the company expanded aggressively into generics and eye care. Vasant Narasimhan, a physician by training who joined Novartis in 2005, took over as CEO in 2018 with a mandate to refocus on high-margin innovative drugs. The firm completed its exit from the Alcon eye-care division in 2019 and spun off its Sandoz generics unit in 2023, leaving a pharmaceutical company centered on oncology, immunology, neuroscience and cardiovascular treatments. The firm's therapeutic focus includes four core areas: oncology, where drugs like Kisqali (breast cancer) and Pluvicto (prostate cancer) anchor the portfolio; immunology with Cosentyx, a multi-billion-dollar interleukin-17 inhibitor; neuroscience anchored by multiple sclerosis drug Kesimpta; and cardiovascular-renal treatments including Entresto, which lost U.S. patent protection in mid-2025. The strategy signals a deliberate bet on high-science, difficult-to-replicate medicines rather than broad primary-care portfolios. The firm's radioligand therapy platform, built on the acquisitions of Advanced Accelerator Applications ($3.9B, 2018) and Endocyte ($2.1B, 2018), represents a key technology differentiation. The company maintains dual global headquarters in Basel, Switzerland, and Cambridge, Massachusetts, employing approximately 78,000 people worldwide as of its 2025 annual report filings. In September 2023, the firm completed the spin-off of Sandoz, distributing shares to Novartis holders and listing the generics unit on the SIX Swiss Exchange (per firm communications, 2023). The Cambridge site houses the Novartis Institutes for BioMedical Research, the company's central R&D engine. The firm does not report AUM in the traditional asset-management sense, but its market capitalization, exceeding $200 billion, reflects the scale of capital it deploys toward R&D and business development, which totaled over $9 billion in 2024. What structurally distinguishes Novartis from similarly sized pharmaceutical peers is its aggressive, decade-long portfolio transformation that eliminated three major business units while doubling down on precision medicine platforms. The decision to exit eye care, consumer health, and generics in sequence — rather than maintaining a diversified healthcare conglomerate — created a narrowing of focus rarely attempted at this scale. The result is a pharmaceutical company whose pipeline concentration on targeted oncology, radioligands, and gene therapies is unmatched among European majors, all overseen by a CEO who is a practicing physician and public-health specialist.
General information
Firm type
Asset Manager
Year founded
1996
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Basel
Corporate office
Basel, Switzerland
Additional offices
Cambridge, MA, United States · East Hanover, NJ, United States
Principals
Vasant Narasimhan
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Novartis's R&D portfolio?
Vasant Narasimhan, CEO since 2018 and a trained physician, works with Chief Scientific Officer Fiona Marshall and CFO Harry Kirsch on major pipeline and acquisition decisions. The board approves large transactions, but day-to-day R&D capital allocation flows through the Novartis Institutes for BioMedical Research and the oncology development unit under Jeff Legos.
How does Novartis source new drug candidates?
Novartis has shifted to a 'buy and build' model, investing heavily in external collaboration alongside internal research. The Cambridge, Massachusetts research hub scouts deals across U.S. biotech hubs, while the Basel headquarters leverages long-standing European academic partnerships. The 2018 purchases of Advanced Accelerator Applications and Endocyte created its radioligand platform, exemplifying its preference for acquiring specific technology platforms over broad pipelines.
Is Novartis structured as a family office or does it operate more like a pharmaceutical company?
Novartis is a publicly traded Swiss pharmaceutical corporation, not a family office or investment firm. It deploys capital internally toward R&D and business development, not third-party investments. The Altss profile covers Novartis because institutional allocators sometimes evaluate it as a peer to large active-investing pools, but its capital is entirely corporate operating capital.
What therapeutic areas does Novartis explicitly avoid?
Under Narasimhan, the firm has retreated from primary care medicines, ophthalmology, and consumer health entirely through its divestitures of Alcon and its consumer joint venture with GSK. It does not have a meaningful presence in vaccines, rare disease outside of gene therapy, or women's health. The current focus is exclusively on patented, specialty pharmaceutical markets.
How is Novartis related to Sandoz?
Sandoz was the generics and biosimilars division of Novartis until its spin-off in September 2023. The two entities now have no ownership link, with Sandoz trading independently on the SIX Swiss Exchange. The separation was designed to allow Novartis to concentrate on higher-margin branded innovative medicines.
Where does Novartis's operating capital come from?
As a publicly traded company, Novartis generates capital from pharmaceutical sales revenue — Cosentyx, Entresto, and Kisqali are among its highest-grossing products — and from debt issuance. Its 2024 annual report disclosed over $9 billion in R&D spending. The firm does not manage any external investor capital; all allocation is from retained earnings and borrowings.
What is Novartis's known posture on in-licensing versus outright acquisition?
Novartis pursues both models but has recently favored outright acquisitions of small to mid-sized biotech platforms over traditional in-licensing deals. The 2018 Endocyte and AAA deals were cash purchases. In November 2024 it announced the acquisition of Kate Therapeutics, a gene therapy company, reinforcing its commitment to buying specific capabilities rather than leasing them through license agreements.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: